Literature DB >> 16696944

A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells.

Lu Qian1, Liyong Chen, Ming Shi, Ming Yu, Baofeng Jin, Meiru Hu, Qing Xia, Xueming Zhang, Beifen Shen, Ning Guo.   

Abstract

Stat3 plays important roles in the development of breast malignancies and oncogenesis. In the present study, a palindromic cis-acting element displaying repression activity in breast cancer cells expressing low level of Her2 was found in Her2 promoter. Deletion analysis showed that the novel element was located within Pal2 region spanning nucleotides -529 to -505. The sequence analysis of Pal2 region revealed a DNA sequence (TTAAGATAA) homologous to the binding site of Stat3, starting from position -529 to -521bp. By reporter assay, Pal2 was found to be regulated by constitutive activated Stat3C. A stimulatory effect both on Her2 mRNA and protein expressions was observed in MCF-7 cells stably expressing Stat3C, suggesting that Stat3 regulated Her2 expression. Using ChIP assays the binding of Stat3 to Her2 promoter was confirmed. The data obtained in this study indicate constitutive activated Stat3 regulates Her2 expression. Further investigation of differential effects of Stat3 exerting on breast cancer cells expressing Her2 at different levels will provide more insights into the roles of Stat3 in Her2 expression as well as the regulation of diverse biological activities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696944     DOI: 10.1016/j.bbrc.2006.04.153

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Special suppressive role of miR-29b in HER2-positive breast cancer cells by targeting Stat3.

Authors:  Ling Qin; Rong Li; Junyi Zhang; Aimin Li; Rongcheng Luo
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

2.  Leptin signaling regulates hypothalamic expression of nescient helix-loop-helix 2 (Nhlh2) through signal transducer and activator 3 (Stat3).

Authors:  Numan Al Rayyan; Jinhua Zhang; Amy S Burnside; Deborah J Good
Journal:  Mol Cell Endocrinol       Date:  2014-01-29       Impact factor: 4.102

Review 3.  The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.

Authors:  A Dittrich; H Gautrey; D Browell; A Tyson-Capper
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-12-28       Impact factor: 2.673

4.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

5.  Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Hannelore Denys; Geert Braems; Ann Nuyts; Rudy Van den Broecke; Veronique Cocquyt; Olivier De Wever; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-06-29       Impact factor: 4.064

6.  MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3.

Authors:  Ying Fu; Jianping Xiong
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

7.  NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.

Authors:  Lili Jiang; Liangliang Ren; Han Chen; Jinyuan Pan; Zhuojun Zhang; Xiangqin Kuang; Xuhong Chen; Wenhao Bao; Chun Lin; Zhongqiu Zhou; Danping Huang; Jianan Yang; Hongbiao Huang; Lan Wang; Ning Hou; Libing Song
Journal:  Cell Death Dis       Date:  2020-07-18       Impact factor: 8.469

8.  Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system.

Authors:  Li-Yu D Liu; Li-Yun Chang; Wen-Hung Kuo; Hsiao-Lin Hwa; Yi-Shing Lin; Meei-Huey Jeng; Don A Roth; King-Jen Chang; Fon-Jou Hsieh
Journal:  Cancer Inform       Date:  2014-01-21

9.  Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.

Authors:  Xia Li; Hongguang Ma; Lin Li; Yifan Chen; Xiao Sun; Zizheng Dong; Jing-Yuan Liu; Weiming Zhu; Jian-Ting Zhang
Journal:  Oncogene       Date:  2018-02-19       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.